Purpose. Patients receiving androgen deprivation therapy undergo a rapid decline in bone mineral density during the first 6 to 12 months of initiating therapy. The World Health Organization has developed and implemented the Fracture Risk Assessment Tool (FRAX) to predict the ten year risk of a major fracture & hip fracture. Additionally, the National Comprehensive Cancer Network and the National Osteoporosis Foundation have developed osteoporosis guidelines. This study aims to characterize the fracture risk (based on the FRAX tool) and the current management of bone health based on national guidelines compliance.
Methods. A retrospective chart review of patients receiving a LHRH agonist at our institution was conducted. Data collection commenced upon Institutional Review Board approval and included demographics, past medical history, medication regimen, history of androgen deprivation therapy, bone health and its management. The ten year fracture risk calculated with the collected information using the FRAX tool.
Results. A total of 174 subjects included with a mean age of 65.5 years, 71.8% had stage II prostate cancer, 97.7% received the LHRH agonist leuprolide for a mean of 13.8 ± 18.1 months. In addition to ADT, 57% of patients had ≥ 2 risk factors for developing osteoporosis. The risk of sustaining a major facture increased from 4% to 5.6% after the initiation of ADT (P = <0.001). The risk for sustaining a hip fracture rose from 1.3% to 2.2% (P = <0.001). National guideline compliance was found to be 9%, 5% and 3% respectively for obtaining Dual Energy X-ray Absorptiometry (DEXA) scans, calcium supplementation, and vitamin D supplementation.
Conclusion. In addition to predisposing risk factors for osteoporosis, ADT significantly increases the fracture risk in the prostate cancer population. There is room for improvement in the management of bone health as some intervention could have been made in over 90% of patients evaluated.
EbelingPR. Clinical practice. Osteoporosis in men. N Engl J Med2008; 358: 1474–1482.
5.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate Cancer. V.1.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2010. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf (accessed 15 February 2010).
6.
WirenKOrwollE. Androgens and bone: basic aspects. In: OrwollE (ed.) Osteoporosis in Men. San Diego: Academic Press, 1999, pp. 211–274.
7.
HiganoCS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol2003; 21: 392–398.
8.
BaillieSPDavisonCEJohnsonFJ. Pathogenesis of vertebral crush fractures in men. Age Ageing1992; 21: 139–141.
9.
JacksonJASpiekermanAM. Testosterone deficiency is common in men with hip fracture after simple falls. Clin Res1989; 37: 131–136.
HiganoCS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really now?. Nat Clin Pract Urol2008; 5(1): 24–34.
13.
OrsiniLSRousculpMDLongSR. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int2005; 16(4): 359–371.
14.
CenterJRNguyenTVSchneiderD. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet1999; 353(9156): 878–882.
15.
SaadFGleasonDMMurrayR. Zoledronic acid prostate cancer study group: a randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. JNatl Cancer Inst2002; 94: 1458–1468.
16.
RyanCWHuoDStallingsJW. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology2007; 70(1): 122–126.
17.
SmithMRMcGovernFJZietmanAL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med2001; 345(13): 948–955.
18.
SmithMREasthamJGleasonDM. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003; 169(6): 2008–2012.
19.
MichaelsonMDKaufmanDSLeeH. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol2007; 25(9): 1038–1042.
TanvetyanonT. Physician practices of bone density testing and drugprescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer2005; 103: 237–241.
22.
DiamondTHHiganoCSSmithMR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer2004; 100: 892–899.
23.
ShahinianVBKuoY-FFreemanJL. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med2005; 352: 154–164.
24.
GreenspanSLCoatesPSereikaSMNelsonJBTrumpDLResnickNM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab2005; 90: 6410–6417.
25.
BollaMTheodordeusMdeReijke. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med2009; 360: 2516–2527.
26.
HorwitzEMBaeKYHanksGE. Ten-year follow-up of RTOG 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol2008; 26(15): 2497–2504.
27.
SouhamiLBaeKPilepichM. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85–31. J Clin Oncol2009; 27: 2137–2143.
28.
Dawson-HughesBHarrisSSKrallEA. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med1997; 337: 670–676.
29.
TrivediDPDollRTee KhawK. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ2002; 326: 469–469.
30.
SmithMREasthamJGleasonDM. Randomized controlled trial of zoledronic acid to prevent bone loss inmen receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol2003; 169: 2008–2012.
31.
KanisJABorgstromFDe LaetC. Assessment of fracture risk. Osteoporos Int2005; 16: 581–589.
32.
WilcoxACarnesMLMoonTD. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother2006; 40: 2107–2114.
